OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 126 filers reported holding OCULAR THERAPEUTIX INC in Q1 2023. The put-call ratio across all filers is 0.49 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,632 | -77.6% | 1,475 | -63.2% | 0.00% | – |
| Q2 2023 | $20,661 | -20.8% | 4,012 | -19.1% | 0.00% | – |
| Q1 2023 | $26,084 | +86.3% | 4,957 | +4.9% | 0.00% | – |
| Q4 2022 | $14,000 | -30.0% | 4,725 | -2.1% | 0.00% | – |
| Q3 2022 | $20,000 | +33.3% | 4,825 | +29.5% | 0.00% | – |
| Q2 2022 | $15,000 | -16.7% | 3,725 | 0.0% | 0.00% | – |
| Q1 2022 | $18,000 | -82.9% | 3,725 | -75.3% | 0.00% | – |
| Q4 2021 | $105,000 | +128.3% | 15,076 | +229.5% | 0.00% | – |
| Q3 2021 | $46,000 | -4.2% | 4,576 | +35.5% | 0.00% | – |
| Q2 2021 | $48,000 | +17.1% | 3,376 | +35.0% | 0.00% | – |
| Q1 2021 | $41,000 | +241.7% | 2,501 | +316.1% | 0.00% | – |
| Q4 2020 | $12,000 | +33.3% | 601 | -47.7% | 0.00% | – |
| Q3 2020 | $9,000 | +28.6% | 1,150 | +27.8% | 0.00% | – |
| Q2 2020 | $7,000 | – | 900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 6,122,089 | $19,223 | 100.00% |
| Opaleye Management Inc. | 6,468,000 | $20,309,520 | 6.61% |
| DELTEC ASSET MANAGEMENT LLC | 2,061,797 | $6,474,043 | 1.48% |
| Endurant Capital Management LP | 353,707 | $1,110,640 | 1.00% |
| SECTORAL ASSET MANAGEMENT INC | 969,350 | $3,043,759 | 0.59% |
| NOTTINGHAM ADVISORS, INC. | 194,266 | $609,995 | 0.09% |
| Covestor Ltd | 37,404 | $117 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 233,582 | $733 | 0.06% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 342,111 | $1,074,229 | 0.03% |
| Polar Asset Management Partners Inc. | 263,763 | $828,216 | 0.02% |